Clinical Trials
2 trialsNCT07015242 2026-03-24
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2 Recruiting
NCT00003293 2012-09-11
SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme
Pfizer
Phase 3 Completed